Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02788773
Title Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications

prostate adenocarcinoma

Therapies

Durvalumab + Tremelimumab

Durvalumab

Age Groups: senior | adult
Covered Countries CAN

Facility Status City State Zip Country Details
BCCA - Cancer Centre for the Southern Interior Kelowna British Columbia V1Y 5L3 Canada Details
BCCA - Vancouver Cancer Centre Vancouver British Columbia V5Z 4E6 Canada Details
CancerCare Manitoba Winnipeg Manitoba R3E 0V9 Canada Details
Juravinski Cancer Centre at Hamilton Health Sciences Hamilton Ontario L8V 5C2 Canada Details
Kingston Health Sciences Centre Kingston Ontario K7L 2V7 Canada Details
London Regional Cancer Program London Ontario N6A 5W9 Canada Details
Ottawa Hospital Research Institute Ottawa Ontario K1H 8L6 Canada Details
Odette Cancer Centre Toronto Ontario M4N 3M5 Canada Details
University Health Network Toronto Ontario M5G 2M9 Canada Details
Allan Blair Cancer Centre Regina Saskatchewan S4T 7T1 Canada Details
Saskatoon Cancer Centre Saskatoon Saskatchewan S7N 4H4 Canada Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field